TTOO (T2 Biosystems) EBIT: $-39.77 Mil (TTM As of Sep. 2024)


TTOO T2 Biosystems Inc TTOO
12 GF Score
Price $0.00
View Full Analysis

What is T2 Biosystems EBIT?

T2 Biosystems TTOO +25.00% 12 EBIT is $-39.77 Mil as of Sep. 2024. GuruFocus rates TTOO with a GF Score™ of 12/100.

T2 Biosystems's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-9.75 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-39.77 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. T2 Biosystems's annualized ROC % for the quarter that ended in Sep. 2024 was -177.35%. T2 Biosystems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -477.12%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. T2 Biosystems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -235.65%.

T2 Biosystems  (OTCPK:TTOO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

T2 Biosystems's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-40.644 * ( 1 - 0% )/( (23.247 + 22.588)/ 2 )
=-40.644/22.9175
=-177.35 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21.721 - 7.277 - ( 4.246 - max(0, 21.799 - 12.996+4.246))
=23.247

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18.082 - 10.143 - ( 2.083 - max(0, 24.435 - 9.786+2.083))
=22.588

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

T2 Biosystems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-38.988/( ( (8.173 + max(0.425, 0)) + (7.745 + max(-3.086, 0)) )/ 2 )
=-38.988/( ( 8.598 + 7.745 )/ 2 )
=-38.988/8.1715
=-477.12 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.297 + 5.169 + 2.284) - (7.277 + 0.237 + 0.811)
=0.425

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.033 + 3.825 + 1.845) - (10.143 + 0.233 + 0.413)
=-3.086

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

T2 Biosystems's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-39.766/16.875
=-235.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

T2 Biosystems EBIT Related Terms

T2 Biosystems EBIT Historical Data

* Premium members only.

The historical data trend for T2 Biosystems's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

T2 Biosystems EBIT Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -51.66 -41.28 -41.65 -55.92 -44.73

T2 Biosystems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.31 -9.18 -12.36 -8.49 -9.75

TTOO vs IDTA, NSTM, TMO: EBIT Comparison

For the Diagnostics & Research subindustry, T2 Biosystems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

T2 Biosystems EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's EV-to-EBIT falls into.


TTOO
12GF Score
T2 Biosystems Inc TTOO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

T2 Biosystems EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-39.77 Mil mean?
T2 Biosystems (TTOO) has a EBIT of $-39.77 Mil as of Sep. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on T2 Biosystems.
Is T2 Biosystems' EBIT too high?
T2 Biosystems' current EBIT is $-39.77 Mil. Overall, T2 Biosystems has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does T2 Biosystems' EBIT compare to IDTA and NSTM?
T2 Biosystems' EBIT of $-39.77 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on T2 Biosystems. T2 Biosystems's current EBIT is $-39.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is T2 Biosystems stock overvalued right now?
T2 Biosystems (TTOO) has a current EBIT of $-39.77 Mil. The current EBIT is $-39.77 Mil. T2 Biosystems' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For T2 Biosystems (TTOO), the current EBIT is $-39.77 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

T2 Biosystems Business Description

Address 101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
12GF Score

Get the complete analysis for TTOO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price